Repligen Corporation (NASDAQ:RGEN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Repligen Corporation (NASDAQ:RGEN) have earned a consensus recommendation of “Moderate Buy” from the eighteen research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, thirteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $165.00.

RGEN has been the topic of a number of research analyst reports. Jefferies Financial Group restated a “hold” rating and issued a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. HC Wainwright upped their price objective on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Roth Capital began coverage on shares of Repligen in a research report on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective on the stock. Evercore restated an “outperform” rating and set a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. Finally, HSBC reduced their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd.

Insider Activity at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

Several institutional investors have recently added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD increased its position in Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC bought a new stake in shares of Repligen in the third quarter valued at about $368,387,000. Opti Capital Management LP bought a new stake in shares of Repligen in the fourth quarter valued at about $2,399,209,000. Wasatch Advisors LP grew its stake in shares of Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after acquiring an additional 346,720 shares in the last quarter. Finally, Maverick Capital Ltd. bought a new position in Repligen during the first quarter worth about $178,946,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Trading Down 1.2%

Repligen stock opened at $145.49 on Thursday. Repligen has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The stock has a market capitalization of $8.21 billion, a P/E ratio of 161.66, a PEG ratio of 2.84 and a beta of 1.06. The stock has a 50-day simple moving average of $129.28 and a 200 day simple moving average of $133.14.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the prior year, the company earned $0.39 earnings per share. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Analysts expect that Repligen will post 1.99 earnings per share for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.